The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

A Senate Committee on Health, Education, Labor and Pension hearing scheduled for Tuesday has all the makings of a showdown as ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company released a statement Monday highlighting the safety of its in-development obesity treatment compared with other ...

The province and Novo Nordisk are accepting proposals from organizations to address childhood obesity and chronic disease in ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing ...